Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Enterprise Value (2018 - 2025)

Neurogene (NGNE) has disclosed Enterprise Value for 5 consecutive years, with -$265.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value fell 90.95% year-over-year to -$265.4 million, compared with a TTM value of -$265.4 million through Sep 2025, down 90.95%, and an annual FY2024 reading of -$312.4 million, changed N/A over the prior year.
  • Enterprise Value was -$265.4 million for Q3 2025 at Neurogene, up from -$274.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$139.0 million in Q3 2024 and bottomed at -$312.4 million in Q4 2024.